Clinical trial · no report yet · Phase 2
NCT02414139
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
- NCT02414139 ↗
- Completed
- Novartis Pharmaceuticals
- 10 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 5 | |
| Podcasts | 3 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Capmatinib
- Arms
- Cohort 1a: Pre-treated patients with MET GCN ≥ 10 (2/3L) · Experimental
- Cohort 1b:Pre-treated patients with MET GCN ≥ 6 and < 10 (2/3L) · Experimental
- Cohort 2: Pre-treated patients with MET GCN ≥ 4 and < 6 (2/3L) · Experimental
- Cohort 3: Pre-treated patients with MET GCN < 4 (2/3L) · Experimental
- Cohort 4: Pre-treated patients with MET mutation regardless of MET GCN (2/3L) · Experimental
- Cohort 5a: Treatment-naïve patients with MET GCN ≥10 (1L) · Experimental
- Cohort 5b: Treatment-naïve patients with MET mutation regardless of MET GCN (1L) · Experimental
- Cohort 6.1 (expansion of Cohort 1a): Pre-treated patients MET GCN ≥ 10 without MET mutation (2L) · Experimental
- Cohort 6.2 (expansion of Cohort 4): Pre-treated patients with MET mutation (2L) · Experimental
- Cohort 7 (expansion of Cohort 5b): Treatment-naïve with MET mutation regardless of MET GCN (1L) · Experimental
- Enrollment
- 373
- Primary outcomes
- Overall Response Rate (ORR) by Blinded Independent Review Committee (BIRC) Assessment
- Sponsor
- Novartis Pharmaceuticals
- Start
- Jun 11, 2015
- Primary completion
- Apr 12, 2023
- Results posted
- Yes
- Registry record
- NCT02414139 · updated Mar 20, 2024
Publications
linked from the registry- Wolf J, Hochmair M, Han JY, Reguart N, Souquet PJ, Smit EF, Orlov SV, Vansteenkiste J, Nishio M, de Jonge M, Akerley W, Garon EB, Groen HJM, Tan DSW, Seto T, Frampton GM, Robeva A, Carbini M, Le Mouhaer S, Yovine A, Boran A, Bossen C, Yang Y, Ji L, Fairchild L, Heist RS. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial. Lancet Oncol. 2024 Oct;25(10):1357-1370. doi: 10.1016/S1470-2045(24)00441-8. PubMed 39362249
- Wolf J, Garon EB, Groen HJM, Tan DSW, Gilloteau I, Le Mouhaer S, Hampe M, Cai C, Chassot-Agostinho A, Reynolds M, Sherif B, Heist RS. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study. Eur J Cancer. 2023 Apr;183:98-108. doi: 10.1016/j.ejca.2022.10.030. Epub 2022 Dec 10. PubMed 36822130
- Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJMoa2002787. PubMed 32877583